Osteoporosis drugs have a reputation problem. Most people picture them as bone-preserving at best — slowing breakdown, not adding new tissue. That impression is accurate for bisphosphonates, which is exactly why a second FDA-approved anabolic peptide often surprises people. If your doctor mentioned abaloparatide, your first questions are probably: Is this just another version of teriparatide? Does it actually work? And why does every drug in this category come with a boxed warning? Those are fair questions with specific, evidence-based answers. Abaloparatide (Tymlos), FDA-approved in 2017, is a synthetic PTHrP-analog peptide that reduced new vertebral fractures by 86% versus placebo in its pivotal trial and offers a modestly different risk profile than teriparatide — but it carries the same firm 24-month lifetime treatment limit and requires a follow-on bisphosphonate to hold its gains.
Summary
Abaloparatide is a 34-amino-acid synthetic analog of parathyroid hormone-related protein (PTHrP), injected daily under the skin to stimulate new bone formation in adults with severe osteoporosis. It is the second anabolic agent approved for osteoporosis after teriparatide (Forteo), approved by the FDA in April 2017 under NDA 208743, and the men's indication was added in 2022.
- What it is: A 34-amino-acid synthetic peptide that mimics the N-terminal region of PTHrP, activating the PTH-1 receptor on osteoblasts to drive bone formation.
- How it works: Daily subcutaneous injection creates a transient PTH-1 receptor signal that tips bone remodeling toward net formation; its receptor binding is more selective than teriparatide's, which translates to a shorter signaling pulse and lower hypercalcemia rates.
- Who it is approved for: Postmenopausal women with osteoporosis at high risk for fracture; men with primary or hypogonadal osteoporosis at high risk for fracture (indication added 2022). High risk means a history of osteoporotic fracture, multiple fracture risk factors, or failure/intolerance of other osteoporosis therapy.
- Duration cap: 24 months cumulative lifetime use, per the FDA-approved label. This limit applies even if courses are separated by years.
- After stopping: BMD gains require consolidation with an antiresorptive. The ACTIVExtend trial demonstrated that 24 months of alendronate after the 18-month abaloparatide course maintained and extended fracture protection.
- Key side effects to know: Orthostatic hypotension (typically within 4 hours of injection), hypercalcemia, and urolithiasis risk — each discussed in detail below.
- Hard stops: Contraindicated in known hypersensitivity to abaloparatide; not indicated in individuals of reproductive potential; avoid in conditions predisposing to osteosarcoma (Paget's disease, prior skeletal radiation, bone malignancy).
What Abaloparatide Is: A Synthetic PTHrP Analog
Your parathyroid glands secrete parathyroid hormone (PTH) when blood calcium drops. A closely related molecule, parathyroid hormone-related protein (PTHrP), is expressed throughout the body — its calcium-raising activity was first identified in cancer patients with hypercalcemia of malignancy. Both PTH and PTHrP act through the same receptor, PTH-1 receptor (PTH1R), expressed on osteoblasts. Abaloparatide was engineered to exploit that shared receptor in a new way.
Abaloparatide is a 34-amino-acid synthetic peptide whose sequence matches PTHrP in the first 20 amino acids, then diverges in 14 engineered substitutions that improve receptor binding and metabolic stability. It shares 41% sequence homology with teriparatide (PTH 1-34) and 76% with PTHrP(1-34).
Teriparatide (Eli Lilly, Forteo) was the first anabolic agent approved for osteoporosis, in 2002. Radius Health's abaloparatide followed in April 2017 under NDA 208743 — the second FDA-approved bone-builder and the first PTHrP-class anabolic. For context on how both fit into the broader landscape, see FDA-approved peptide drugs.
How Abaloparatide Works: Selective PTH1R Signaling
Here is where abaloparatide makes its scientific case for being more than a me-too version of teriparatide. PTH1R exists in two conformational states, called R0 and RG. Teriparatide binds with high affinity to both states — it has roughly four times higher affinity for the R0 state than PTHrP does. The R0 state is the long-lived, GTPgamma-S-insensitive conformation that produces a sustained signaling response. When teriparatide locks into R0, it generates a prolonged cAMP cascade inside osteoblasts, which explains both its strong anabolic signal and its tendency to also ramp up RANKL expression — the signal that recruits osteoclasts and eventually erodes the anabolic window.
Abaloparatide, by contrast, binds strongly to the RG state but has much weaker R0 affinity, producing a more transient signaling pulse (PMID 26562265). Think of it as a door that opens and closes faster: the osteoblasts get the "build bone" signal without the prolonged downstream stimulation that also activates bone resorption machinery. The result, confirmed in animal studies and in the clinical trial, is a stronger ratio of bone formation to bone resorption compared with teriparatide — and meaningfully lower rates of hypercalcemia.
A 2019 review in Frontiers in Pharmacology summarized the mechanistic case: "Abaloparatide presented a potent anabolic activity with reduced effects on bone resorption as compared to teriparatide, which may be due to a more transient signaling response related to differing affinities to specific conformations of the PTH1 receptor" (PMID 31136739). That theoretical advantage translates, in the ACTIVE trial, into a measurable clinical difference: hypercalcemia occurred in 3.4% of the abaloparatide group versus 6.4% in the teriparatide arm — a statistically significant difference (P = 0.006).
The ACTIVE Trial: What the Phase 3 Evidence Shows
The pivotal evidence for abaloparatide comes from the ACTIVE trial (Abaloparatide Comparator Trial In Vertebral Endpoints), NCT01343004. Miller et al. published the primary results in JAMA in August 2016, before FDA approval — a placebo-controlled, double-blind Phase 3 randomized trial that also included an open-label teriparatide arm for head-to-head comparison (PMID 27533157).
Trial design: 2,463 postmenopausal women with osteoporosis, mean age 69, randomized to daily subcutaneous abaloparatide 80 mcg (n=824), placebo (n=821), or open-label teriparatide 20 mcg (n=818) for 18 months. The primary endpoint was new morphometric vertebral fracture.
Primary outcome: New vertebral fractures occurred in significantly fewer women in the abaloparatide group than in the placebo group (absolute rates not reported in the abstract, but the Kaplan-Meier analysis showed an 86% relative risk reduction). The teriparatide arm showed comparable vertebral fracture protection.
Nonvertebral fractures: This is where abaloparatide showed a potentially meaningful edge. Kaplan-Meier estimated nonvertebral fracture incidence was 3.0% in the abaloparatide group versus 5.3% in the placebo group — a 43% relative risk reduction. The teriparatide arm showed 3.0% incidence as well, though the trial was not powered to make a head-to-head comparison between the two active treatments.
Major osteoporotic fractures: 1.6% with abaloparatide versus 6.8% with placebo, a striking absolute difference.
Bone mineral density: BMD gains at the lumbar spine, total hip, and femoral neck were all significantly greater with abaloparatide than placebo (all P < 0.001). Detailed gains favored abaloparatide over teriparatide at the total hip and femoral neck in the 18-month window, consistent with the hypothesis that the more transient receptor signal produces proportionally greater cortical bone gain.
Safety headline from ACTIVE: The trial confirmed orthostatic hypotension as a class-level concern alongside the hypercalcemia difference already noted, and confirmed general tolerability of daily self-injection.
ACTIVExtend: Sequential Therapy Locks In the Gains
Stopping any anabolic agent without follow-on therapy is not clinically viable — BMD gains erode within 12 months. The ACTIVExtend study (PMID 28160873) enrolled women from ACTIVE into a 24-month open-label extension, giving all participants weekly alendronate 70 mg regardless of prior assignment. The critical comparison: abaloparatide-then-alendronate versus placebo-then-alendronate over the full 43-month period.
Vertebral fractures over 43 months: 0.55% in the abaloparatide/alendronate group versus 4.4% in the placebo/alendronate group — an 87% relative risk reduction (relative risk 0.13; 95% CI 0.04 to 0.41; P < 0.001).
Nonvertebral fractures: 2.7% versus 5.6%, a 52% risk reduction (HR 0.48; 95% CI 0.26 to 0.89; P = 0.02).
BMD at 25 months from baseline: Lumbar spine gains of 12.8% versus 3.5%; total hip 5.5% versus 1.4%; femoral neck 4.5% versus 0.5% — all with P < 0.001.
ACTIVExtend confirms that abaloparatide primes the skeleton for a stronger bisphosphonate response — the bone formed during the anabolic phase gives the antiresorptive more high-quality matrix to protect. This is the basis for the "anabolic-first, antiresorptive-second" sequencing now endorsed for severe osteoporosis, discussed in the companion teriparatide article.
Side Effects and Safety: What the Label Says
Abaloparatide is a prescription medication with real risks that deserve explicit discussion.
Orthostatic hypotension. The Tymlos prescribing label (accessdata.fda.gov/drugsatfda_docs/label) warns that orthostatic hypotension may occur "typically within 4 hours of injection" and may be accompanied by dizziness, palpitations, or nausea. The label recommendation: administer the first several doses in a setting where the patient can sit or lie down if needed, and observe for approximately 1 hour. This is a practical safety consideration, not a rare theoretical risk.
Hypercalcemia. Because abaloparatide stimulates bone formation and calcium mobilization, blood calcium can rise. The label advises against use in patients with pre-existing hypercalcemia or primary hyperparathyroidism, conditions that already raise serum calcium. Periodic serum calcium monitoring is appropriate, particularly in the early months of therapy.
Urolithiasis. Increased urinary calcium excretion creates a theoretical risk of kidney stone formation. The label recommends monitoring urinary calcium in patients with active urolithiasis or a history of hypercalciuria. This is not a blanket contraindication but warrants individual assessment.
Osteosarcoma — the boxed warning. Abaloparatide caused dose-dependent osteosarcoma in rats at exposures 4 to 28 times the clinical dose. This has not been observed in human epidemiological data, but the black box stands and the label excludes patients with Paget's disease, prior skeletal radiation, bone metastases, open epiphyses, or hereditary osteosarcoma predisposition.
Pregnancy. Tymlos is not indicated for individuals of reproductive potential. The contraindication is explicit, though the approved population — postmenopausal women and adult men — makes pregnancy exposure unlikely.
The 24-Month Limit and Sequential Bisphosphonate
The FDA label states directly: "Use of the drug for more than 2 years during a patient's lifetime is not recommended." Cumulative means cumulative — a patient who completes 12 months, stops for years, and restarts has 12 months remaining. The limit reflects both the rodent osteosarcoma signal and the diminishing returns in bone formation markers seen in longer human treatment.
After completing the abaloparatide course, transition to an antiresorptive — typically alendronate, risedronate, or zoledronic acid. The ACTIVExtend data are explicit: this step preserves and extends fracture protection. Stopping without follow-on therapy is a clinical error; the evidence leaves no ambiguity.
One point that surprises many patients: the 2-year cumulative limit is shared between abaloparatide and teriparatide. A patient cannot take 18 months of each consecutively — the limit covers both agents together. The teriparatide article covers that shared cap in full detail.
Abaloparatide vs. Teriparatide: How Do They Actually Compare?
Both drugs activate PTH1R, are given as daily subcutaneous injections, carry the same 24-month cumulative lifetime cap, and require sequential antiresorptive therapy. The differences are real but selective.
Hypercalcemia rate. The ACTIVE trial's most clinically actionable finding was a statistically significant lower rate of hypercalcemia with abaloparatide (3.4%) versus teriparatide (6.4%), P = 0.006. For patients with borderline serum calcium or primary hyperparathyroidism, this matters.
Fracture data. Both drugs showed strong vertebral fracture protection versus placebo. ACTIVE included a teriparatide arm but was not powered for a head-to-head fracture comparison. Abaloparatide showed a 43% nonvertebral fracture reduction versus placebo; teriparatide's comparable figure from its own trial was 28%, though these numbers are not directly comparable across separate studies.
BMD at cortical sites. Abaloparatide showed numerically greater gains at the total hip and femoral neck during ACTIVE, consistent with its more transient PTH1R signal preferentially driving cortical bone. The full mechanistic and sequencing discussion is in the companion teriparatide article.
Cost and biosimilar access. Teriparatide now has a biosimilar (Bonsity, 2023). Abaloparatide has none as of this writing, which affects formulary decisions. Both require prior authorization.
Men's indication. Teriparatide has carried an explicit men's indication since 2002. Abaloparatide's men's indication was added in 2022 based on a 12-month trial in men aged 42 to 85 (n=228) showing significant BMD gains at all measured sites.
Neither drug is clearly dominant across all patients. The practical choice comes down to prescriber experience, insurance formulary, and individual comorbidities — particularly existing hypercalcemia risk.
Who Is a Candidate for Abaloparatide?
Abaloparatide is not a therapy for borderline low bone density. The FDA-approved indications are specific:
- Postmenopausal women with osteoporosis at high fracture risk — meaning prior fracture, multiple risk factors, or failure/intolerance of other therapy.
- Men with primary or hypogonadal osteoporosis at high fracture risk (indication added 2022).
Anabolic agents are reserved for the severe end of the spectrum. They carry a boxed warning, require daily self-injection, and cost far more than bisphosphonates. Standard care still starts with antiresorptives; abaloparatide enters when first-line therapy has been insufficient.
For a broader look at bone health and peptides across life stages, the peptides-for-women-over-40 overview covers the wider landscape.
Frequently Asked Questions
Is abaloparatide the same drug as teriparatide? No. They target the same receptor but are structurally distinct — abaloparatide is a PTHrP analog; teriparatide is a PTH analog. Their clinical differences include hypercalcemia rates and cortical-versus-trabecular BMD patterns.
Can I take it longer than 2 years if it is working? No. The FDA label specifies a 2-year cumulative lifetime maximum. This is a hard limit, not a dosing suggestion.
What happens when I stop? Without a follow-on antiresorptive, most BMD gain is lost within 12 months. Plan the transition to a bisphosphonate before the final abaloparatide doses, not after.
Is it approved for men? Yes, since 2022. The indication covers primary or hypogonadal osteoporosis at high fracture risk.
Can it cause kidney stones? Increased urinary calcium excretion raises that risk. Patients with a history of kidney stones or hypercalciuria should be monitored and may need modified management.
Are there drug interactions? No major pharmacokinetic interactions are listed in the label, but calcium supplements, thiazide diuretics, and high-dose vitamin D can compound hypercalcemia risk. Review your full medication list with your prescriber.
Conclusion
Abaloparatide (Tymlos) occupies a specific, well-defined role: an anabolic peptide for severe, high-fracture-risk osteoporosis in postmenopausal women and — since 2022 — in men with primary or hypogonadal osteoporosis. Its pivotal trial data are strong, its sequential therapy strategy is validated across 43 months, and its modestly lower hypercalcemia rate relative to teriparatide may guide the choice between the two drugs in individual cases.
What it is not is a shortcut, a supplement, or a therapy for mild low bone density. It carries a boxed warning, a hard 24-month lifetime cap, mandatory follow-on bisphosphonate therapy, and daily self-injection. Those constraints reflect genuine tradeoffs, not bureaucratic caution.
The right question for your prescriber is not "which bone-building peptide is best?" but rather "is anabolic therapy indicated for me, and which agent fits my fracture history, calcium status, and formulary?" That conversation requires a DXA scan and a FRAX score — not a blog article.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Tymlos (abaloparatide) is a prescription medication approved by the FDA for specific indications. Only a licensed healthcare provider can determine whether abaloparatide or any other osteoporosis therapy is appropriate for your individual situation. Do not start, stop, or change any medication based on information in this article.
